Jane B. Brock
A5084636752- Ferrocene Chemistry and Applications
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Genomics and Chromatin Dynamics
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Cellular Mechanics and Interactions
- Breast Cancer Treatment Studies
- FOXO transcription factor regulation
- Silk-based biomaterials and applications
- Immunotherapy and Immune Responses
- Adipose Tissue and Metabolism
- Metabolism, Diabetes, and Cancer
- Cancer Risks and Factors
- Hair Growth and Disorders
- Biochemical and Structural Characterization
- Immune cells in cancer
- Angiogenesis and VEGF in Cancer
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- CAR-T cell therapy research
- Ferroptosis and cancer prognosis
- HER2/EGFR in Cancer Research
Brigham and Women's Hospital
2014-2024
Harvard University
2014-2024
Dana-Farber Brigham Cancer Center
2018
Dana-Farber Cancer Institute
2018
University of Rostock
1997
University College London
1996
Significance Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates morphology to improve function we conducted a phase II trial of preoperative followed by combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response may occur through an increase extent vascular normalization primarily high baseline tumor microvessel density. If validated, these...
Small skin wounds in the chick embryo do not heal by lamellipodial crawling of cells at wound edge as a does adult, but rather contraction an actin purse-string that rapidly assembles front row epidermal (Martin, P., and J. Lewis. 1992. Nature (Lond.). 360:179-183). To observe early time course assembly to characterize other cytoskeletal components contractile machinery, we have followed healing incisional or slash on dorsum wing; these take only seconds create within approximately 6 h....
Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on biology remains understudied humans. This study investigates how the untreated primary differs according to patients' body mass index (BMI) using data from >2,000 patients. We identify several genomic alterations that are differentially prevalent overweight or obese patients compared lean report evidence supporting ageing accelerating effect obesity at genetic...
Abstract Most invasive lobular breast cancers (ILC) are of the luminal A subtype and strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen associated with inferior long-term outcomes compared ductal (IDC). In this study, we sought gain mechanistic insights into these clinical findings that not explained by genetic landscape identify strategies improve patient outcomes. comprehensive analysis epigenome in preclinical models samples showed that, IDC, harbored a...
It is generally believed that the strength and structural integrity of both adult embryonic epithelia comes, at least in part, from their internal cytoskeletal network keratin filaments associated cell:cell junctions. Indeed, recent depletion experiments Xenopus suggest capacity to undergo natural morphogenetic movements such as gastrulation, or artificially triggered epithelial wound closure, are severely compromised absence predominant keratin, K8 [Torpey et al., 1992: Nature 357:413–415;...
For patients with metastatic triple-negative breast cancer (TNBC), treatment pembrolizumab is dependent on the accurate determination of programmed death ligand 1 (PD-L1) expression using immunohistochemistry (IHC). This study evaluated interobserver concordance in assessing PD-L1 TNBC samples commercial 22C3 IHC assay and an in-house based E1L3N antibody. Concordance between assays was read by a laboratory Brigham Women’s Hospital pathologist (BWH reader). Each slide given combined positive...
Abstract Background: Hormone receptor-positive (HR+) tumors have fewer tumor-infiltrating lymphocytes (TILs) and lower response rates to immune checkpoint inhibitors (ICI), either as single agents or in combination with chemotherapy, than triple negative cancers. However, some HR+ cancers do respond ICI biomarkers that accurately reflect the microenvironment may help guide use of therapy. Prior evidence suggests macrophage-related pathways be relevant pathophysiology BC. Methods: HR+/HER2-...
Abstract Introduction: Antibody-drug conjugates (ADC) are designed to effectively deliver cytotoxic agents directly malignant cells. Trastuzumab deruxtecan (Tdx), an ADC of trastuzumab, enzyme-cleavable linker, and a topoisomerase I inhibitor, has been shown have antitumor activity in patients with breast cancer low levels HER2. However, current companion diagnostic tests for HER2-targetting therapies, immunohistochemistry (IHC) fluorescent situ hybridization (FISH), were optimized high...
Abstract Worldwide, there is a growing proportion of women who are overweight or obese. While obesity has been associated with an increased risk developing breast cancer (BC) and worse prognosis in BC patients, yet the impact adiposity (abnormal excess body fat) on biology remains understudied humans. This retrospective study aimed to investigate how primary would differ according patients’ mass index (BMI). We examined clinicopathological data (including BMI at time diagnosis) molecular...
<div>Abstract<p>Most invasive lobular breast cancers (ILC) are of the luminal A subtype and strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen associated with inferior long-term outcomes compared ductal (IDC). In this study, we sought gain mechanistic insights into these clinical findings that not explained by genetic landscape identify strategies improve patient outcomes. comprehensive analysis epigenome in preclinical models samples showed that,...
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer